Wang L.-H.Tsai M.-J.WEN-YU TSAILee J.-S.BOR-LUEN CHIANG2021-07-022021-07-0220000929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033836463&partnerID=40&md5=7f5167db8b0ca21f26de3368598aab8bhttps://scholars.lib.ntu.edu.tw/handle/123456789/568083Propylthiouracil (PTU), a drug commonly used for treatment of hyperthyroidism, is associated with various rare side effects. Antineutrophil cytoplasm antibody (ANCA)-positive vasculitis is a relatively unusual complication among them. The pathogenesis of ANCA-positive vasculitis during PTU therapy is still obscure. We present the case of a 12-year-old boy who developed ANCA-positive vasculitis during PTU therapy for Graves' disease. His symptoms and signs were indistinguishable from anaphylactoid purpura, a common small-vessel vasculitis in children. The clinical manifestations improved after discontinuation of PTU and immunosuppressant treatment. He remained symptom-free at 11-months follow-up.Antibody; Antineutrophil cytoplasm; Child; Propylthiouracil; Vasculitis[SDGs]SDG3azathioprine; hydroxychloroquine; naproxen; neutrophil cytoplasmic antibody; prednisolone; propylthiouracil; thiamazole; arthritis; article; case report; clinical feature; drug effect; epigastric pain; episcleritis; fever; Graves disease; human; male; microcytic anemia; rash; school child; scleritis; symptom; treatment outcome; vasculitis; Antibodies, Antineutrophil Cytoplasmic; Antithyroid Agents; Child; Graves Disease; Humans; Male; Propylthiouracil; Purpura, Schoenlein-Henoch; Vasculitisjournal article109695082-s2.0-0033836463